Chad W. Rice

FDA investigator

Appears on 8 documents from 2023 to 2026, most often at sites in India. Most often cites control of microbiological contamination (21 CFR 211.113(a)).

8
Documents on file
2.6
Observations per 483
2023
First seen
2026
Most recent

What they cite most

From 21 observations

Activity by year

2023: 2, 2025: 4, 2026: 2

Where

India 2 · Illinois 1 · Japan 1 · Kansas 1 · Missouri 1 · Nebraska 1

Is Chad W. Rice coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

8 documents, newest first
FirmOpen
483 Staska Pharmaceuticals, Inc.Feb 20, 2026 · Bennet, Nebraska
483 Nice-Pak Products, LLCFeb 5, 2026 · Saint Louis, Missouri
483 Lupin LimitedSep 16, 2025 · Nagpur, India
483 Chugai Pharma Manufacturing Co., LtdJul 4, 2025 · Fujieda, Japan
483 Form 483 · FEI 3010166683Feb 21, 2025 · Balisinor, India
483 Hospira, Inc.Jan 17, 2025 · McPherson, Kansas
483 Fresenius Kabi USA, LLCAug 24, 2023 · Melrose Park, Illinois

About this profile

What does Chad W. Rice inspect?

Chad W. Rice appears on 8 documents on file covering 8 sites, most often in India.

What do they cite most often?

21 CFR 211.113(a) (control of microbiological contamination), followed by 21 CFR 211.192 and 21 CFR 211.22.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Chad W. Rice is dated Feb 20, 2026.